Press releases
2019
16 October, 2019
PledPharma approved for listing on Nasdaq Stockholm
21 August, 2019
Half-Year report January-June 2019
15 July, 2019
The Lancet EBioMedicine publishes Aladote® study results
11 July, 2019
Aladote® – regulatory interactions
21 May, 2019
PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million
6 May, 2019
Interim report January-March 2019
12 April, 2019
PledPharma's drug candidate Aladote® is highlighted at one of the largest liver conferences globally
8 April, 2019
NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB
8 April, 2019
PledPharma’s 2018 annual report published
26 March, 2019
PledPharma will be presenting company’s drug development programs at today’s CMD in Stockholm
14 March, 2019
PledPharma Capital Markets Day, March 26
21 February, 2019
Year-end Report January-December 2018
5 February, 2019
PledPharma Capital Markets Day
31 January, 2019
Aladote®’s data has been selected for presentation at The International Liver Congress
17 January, 2019
PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium